Pharmaceutical - AstraZeneca, Markets & Marketing

Filter

Popular Filters

1 to 25 of 39 results

Pharmaceuticals, a strategic sector for the UK government

Pharmaceuticals, a strategic sector for the UK government

28-07-2014

Britain’s pharmaceuticals sector, which includes AstraZeneca and GlaxoSmithKline, two drugmakers among…

AstraZenecaEconomy of the United KingdomFinancialGlaxoSmithKlineMarkets & MarketingPharmaceuticalResearchUK

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

01-07-2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1…

AstraZenecaBristol-Myers SquibbEuropeJapanMarkets & MarketingMED14736Merck & ConivolumabOncologypembrolizumabPharmaceuticalResearchRocheUSAYervoy

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

Lack of pricing accord sees Bristol-Myers and AstraZeneca pull Forxiga in Germany

14-12-2013

Drug majors Bristol-Myers Squibb and AstraZeneca have reportedly decided to stop marketing their diabetes…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaMarkets & MarketingPharmaceuticalPricing

Modest growth forecast for global CD market

02-12-2013

The global market for cardiovascular disease - comprised of heart failure, myocardial infarction and…

AstraZenecaAZD6140BAY81-8781BayerCardio-vascularLCZ696Markets & MarketingNovartisPharmaceuticalPricingserelaxin

What does the future hold for pharma?

What does the future hold for pharma?

22-11-2013

Here's our take on the week's top stories.

AstraZenecaBayerBiotechnologyCerulean PharmaMarkets & MarketingPharmaceuticalResearchSanofi

Opioid-induced constipation market expected to see rapid growth by 2017

Opioid-induced constipation market expected to see rapid growth by 2017

13-10-2013

The global market for opioid-induced constipation will increase significantly from $144.42 million in…

AstraZenecabevenopranCubist PharmaceuticalsEuropeGastro-intestinalsMarkets & MarketingnaloxegolNorth AmericaPharmaceuticalRelistorSalix Pharmaceuticals

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

11-10-2013

Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

AstraZeneca’s naloxegol marketing application accepted by EMA

AstraZeneca’s naloxegol marketing application accepted by EMA

27-09-2013

The European Medicines Agency has accepted AstraZeneca’s Marketing Authorization Application for naloxegol…

AstraZenecaEuropeGastro-intestinalsMarkets & MarketingnaloxegolNektar TherapeuticsPharmaceuticalRegulation

AstraZeneca's starts olaparib in Ph III for ovarian cancer

04-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has enrolled the first patient in the Phase III…

AstraZenecaMarkets & MarketingMyriad GeneticsolaparibOncologyPharmaceuticalResearch

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData

18-07-2013

Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Emerging targeted therapies offer advantages over currently-used platinum-resistant ovarian cancer drugs

11-06-2013

The effect of an emerging therapy on key efficacy endpoints, including time to disease progression and…

AmgenAstraZenecaAvastinBiotechnologyMarkets & MarketingMerck & CoNorth AmericaolaparibOncologyPharmaceuticalRochetrebananibvintafolide

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules

27-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe

22-04-2013

Anglo-Swedish drug major AstraZeneca and BIND Therapeutics, a US clinical-stage biopharmaceutical, have…

AstraZenecaBIND TherapeuticsBiotie TherapiesEuropeKymabLundbeckMarkets & MarketingNovo NordiskOncologyPharmaceuticalResearchSelincro

AstraZeneca to invest $1.2 billion in Russia by 2017; Pharmstandard deal with AVVA

28-12-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) plans to invest up to $1.2 billion in its development…

AstraZenecaAVVA PharmaceuticalsEuropeFinancialMarkets & MarketingPharmaceuticalPharmstandardProduction

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26-11-2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

Russian prostate cancer market expected to grow 6% annually from 2011 to 2016

01-11-2012

The total number of diagnosed incident cases of prostate cancer in Russia will increase at five percent…

AstraZenecaBuserelinEuropeMarkets & MarketingOncologyPharm-SintezPharmaceuticalZoladex

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

AstraZeneca's Brilinta rolls out in India

18-10-2012

The Indian subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched its patented…

Asia-PacificAstraZenecaBrilintaCardio-vascularMarkets & MarketingPharmaceutical

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16-10-2012

The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021

16-09-2012

The rheumatoid arthritis drug market will experience modest growth over the next decade as sales increase…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibGlobalMarkets & MarketingPfizerPharmaceuticalTakeda Pharmaceuticalstofacitinib

1 to 25 of 39 results

Back to top